Zanoprima Lifesciences

What Zanoprima Lifesciences does

Zanoprima Lifesciences is a privately held UK life-sciences company founded in 2014 in London that has developed and patented a cost-effective enzymatic process for synthesizing high-purity (typically 99.9%) synthetic (S)-nicotine marketed as SyNic. Unlike tobacco-derived nicotine or racemic synthetic mixtures, SyNic delivers the natural-type (S)-isomer free of tobacco-specific nitrosamines, related tobacco alkaloids, odour, and harsh taste, and conforms to European and US Pharmacopeia specifications. The company sells SyNic as a bulk B2B ingredient in multiple formulations (free base, bitartrate dihydrate SyNic-BT, polacrilex resin SyNic-PX, and a patented protonated e-liquid) to pharmaceutical companies manufacturing NRTs, vape and e-cigarette producers, and modern oral nicotine product manufacturers. Manufacturing takes place in an FDA-approved, cGMP-compliant facility with approvals from MHRA, TGA, ANVISA, and South Africa's Marketing Code Authority, and a CEP application is in process with EDQM.

Beyond ingredient supply, Zanoprima has developed a portfolio of branded consumer products — Zanoz nicotine pouches, Zanoz chewing gum and lozenges, and Znus tobacco-free white snus — which are positioned for licensing and partnership arrangements and are progressing through US FDA regulatory approval. Pipeline products include skin-friendly transdermal patches targeted at Parkinson's disease and age-related cognitive decline, and a tobacco-free heated nicotine product. The underlying patents are granted in over 35 countries and were successfully enforced in a 2023 US District Court (Texas) ruling against Hangsen International Group.

The company operates with 1-10 employees from its registered office in Camden Town, London. Following the death of founder Ashok Narasimhan in October 2023, his son Anand Ashok joined the board in January 2025 and was appointed CEO in March 2025 with responsibility for global operations and strategic growth. Go-to-market is enterprise sales-led for bulk SyNic supply, complemented by licensing and partnership channels for the Zanoz and Znus brands; pricing for SyNic is described as competitive with pharmaceutical-grade tobacco-derived nicotine and cheaper than competing synthetic forms.

Name

Zanoprima Lifesciences

Legal name

Zanoprima Lifesciences Limited

Website

https://zanoprima.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Zanoprima Lifesciences is a UK-based life-sciences company that manufactures and sells SyNic, a patented high-purity synthetic (S)-nicotine, as a B2B ingredient to pharmaceutical NRT manufacturers, vape producers, and modern oral nicotine product makers, and develops its own Zanoz and Znus branded nicotine products for licensing.

Ownership category

akta.pro rank

Product category

Synthetic Nicotine Manufacturing

NAICS

Tobacco Manufacturing (312230), Beverage and Tobacco Product Manufacturing (312)

SIC

Tobacco Products (2100), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Nicotine Pouches (Tobacco-Free) Manufacturing & Brands (CRADAJAI)

akta.pro secondary industries

E-liquids & Nicotine Salts Manufacturing & Brands (CRADAJAG), Smokeless Tobacco (Chewing Tobacco, Snuff, Snus) Manufacturing & Brands (CRADAJAC)

Keywords

• Synthetic nicotine
• Pharmaceutical ingredients
• Nicotine replacement therapy
• Tobacco-free nicotine
• Nicotine pouches

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SyNic (S)-Nicotine Bulk Supply: Zanoprima manufactures and sells its patented SyNic synthetic (S)-nicotine as a raw material/ingredient to manufacturers of nicotine products including vapes, nicotine pouches, snus, heated tobacco products, and nicotine replacement therapies. This is the primary revenue stream as a B2B ingredient supplier.
2. Zanoz Branded Consumer Products: Zanoprima has developed its own branded product line (Zanoz nicotine pouches, Zanoz chewing gum and lozenges) which are undergoing U.S. FDA regulatory approval. These products may be available for licensing or partnership arrangements.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Zanoprima Lifesciences manufactures and supplies SyNic, the world's first high-purity (typically 99.9%) synthetic (S)-nicotine produced via a patented enzymatic process that does not derive nicotine from tobacco. The company sells this ingredient as a B22B raw material to pharmaceutical companies, vape manufacturers, and nicotine product makers, and has developed branded consumer formats (Zanoz pouches, chewing gum, lozenges; Znus snus) for licensing and partnership.

Product overview

Zanoprima Lifesciences is a life sciences company that has developed and patented a cost-effective process to create innovative nicotine products. The core product is SyNic (S)-Nicotine, a high-purity (typically 99.9%) synthetic nicotine available in multiple formulations including free base, bitartrate dihydrate (SyNic-BT), and polacrilex resin (SyNic-PX). The product portfolio includes consumer-facing brands: Znus (tobacco-free white snus) and Zanoz product line (nicotine pouches, chewing gum, and lozenges). The company also offers protonated (S)-Nicotine e-liquid for e-cigarettes and is developing transdermal patches and heated nicotine products. SyNic products conform to European Pharmacopeia (EP) and US Pharmacopeia (USP) specifications and are manufactured in FDA-compliant cGMP facilities.

Differentiator

Problem solved

Functional benefit

Brands

• SyNic: World's first synthetic, high purity (typically 99.9%) (S)-nicotine that is neither derived from any part of the tobacco plant nor from a synthetic racemic mixture. Patented enzymatic process product.
• Zanoz
• Znus

Products and services

• SyNic (S)-Nicotine Synthetic, high chemical purity (typically 99.9%) (S)-nicotine free base that is neither derived from tobacco nor from a synthetic racemic mixture. Conforms to and exceeds European Pharmacopeia and United States Pharmacopeia specifications. Supplied as a bulk ingredient to manufacturers of vapes, nicotine pouches, snus, heated tobacco products, and nicotine replacement therapies.
• SyNic (S)-Nicotine bitartrate dihydrate (SyNic-BT) A bitartrate dihydrate salt form of SyNic (S)-nicotine conforming to and exceeding European Pharmacopeia specifications. Designed for use in modern oral nicotine products such as nicotine pouches.
• SyNic (S)-Nicotine polacrilex resin (SyNic-PX) A polacrilex resin / nicotine resinate form of SyNic (S)-nicotine at 18% and 20% concentrations, conforming to and exceeding European Pharmacopeia and United States Pharmacopeia specifications. Used in oral nicotine products such as chewing gums, lozenges, and pouches.
• Protonated (S)-Nicotine E-Liquid Patented protonated (S)-nicotine e-liquid for e-cigarettes, formulated without organic acids and propylene glycol. Provides high purity, stability, long shelf life, and smooth taste for vape manufacturers.
• Znus Tobacco-Free White Snus Sodium-free, tobacco-free white snus containing buffered free nicotine that provides instant burst followed by sustained release, offering smooth taste without the odor and harshness associated with natural nicotine.
• Zanoz Nicotine Pouches Sodium-free next generation oral nicotine pouches using a proprietary formula of free nicotine stabilized by a solid support, delivering nicotine smoothly via sustained release.
• Zanoz Chewing Gum and Lozenges Chewing gum and lozenges that deliver an instant burst of nicotine followed by sustained release, formulated with a proprietary nicotine complex for superior taste and no sodium content.

Quantifiable outcome

• SyNic typically achieves 99.9% chemical purity — described as the purest form of nicotine on the market
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Hangsen International Group: Hangsen is a major global e-liquid and nicotine manufacturer that was sued by Zanoprima for patent infringement of the enzymatic (S)-nicotine synthesis process. The two companies compete in supplying nicotine ingredients to vape brands, with the 2023 Texas court ruling affirming Zanoprima's IP position.
• Contraf-Nicotex-Tobacco (CNT): CNT is one of the world's largest independent suppliers of pharmaceutical-grade tobacco-derived nicotine to NRT and e-cigarette manufacturers. Zanoprima competes head-to-head with CNT by offering a synthetic alternative at price parity with pharmaceutical-grade plant-derived nicotine.
• Next Generation Labs: Next Generation Labs (NGL) developed and supplies a synthetic racemic nicotine ('TFN' — Tobacco-Free Nicotine) to vape manufacturers. Zanoprima competes with NGL via its chiral (S)-only synthetic process, positioning SyNic as a higher-purity, higher-spec alternative in the same synthetic nicotine category.

Broad incumbents

• NJOY Holdings: NJOY is a US vape company that was the subject of an early synthetic nicotine-related FDA authorization. As a vape brand that has navigated FDA review of synthetic-nicotine products, NJOY is both a potential customer for SyNic e-liquid and an example of the regulatory roadmap for synthetic-nicotine consumer products.
• Japan Tobacco International: JTI is a global tobacco and reduced-risk product company with a strong modern oral portfolio and heated tobacco investments. Its global regulatory footprint makes it a potential multi-region enterprise customer for SyNic inputs and a comparable scaled incumbent investing in next-generation nicotine.
• Philip Morris International: PMI is a global tobacco and nicotine leader with extensive R&D into smoke-free products and heated tobacco. PMI is both a potential enterprise customer for SyNic and a strategic competitor as it invests in reduced-risk and synthetic nicotine products across its portfolio.
• Turning Point Brands: Turning Point Brands sells modern oral nicotine (Rogue pouches), vaping products, and other smoke-free alternatives, putting it in the same enterprise customer category as Zanoprima's B2B ingredient buyers while being a potential partner or licensing counterparty for Zanoz-branded pouches.
• British American Tobacco: BAT operates a broad portfolio of combustibles, modern oral nicotine (Velo/Grizzly), and vape brands. Its category-leading position in nicotine pouches makes it a target customer for Zanoprima's SyNic-BT and SyNic-PX ingredients, while its scale and R&D make it a long-term competitor in next-gen nicotine.
• Swedish Match: Swedish Match is the dominant player in snus and nicotine pouches (Zyn, General) and a likely enterprise customer for tobacco-free nicotine such as SyNic. Its deep expertise in pouches makes it comparable to Zanoprima in modern oral nicotine, though Swedish Match is far larger and not synthetic-nicotine-focused.
• GSK Consumer Healthcare (Nicotinell): GSK's Nicotinell brand is one of the largest global NRT product lines (gums and patches). It is a strategic enterprise customer for Zanoprima's pharmaceutical-grade SyNic and SyNic-PX resin for NRT manufacturing, and a comparator because it sits at the top of the NRT supply chain Zanoprima serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zanoprima

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zanoprima Lifesciences